ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, today announced the enrollment of the first patient in its Phase ...

RION's Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU). Diabetic ...

Lonza agreed to provide cGMP manufacturing and technical support for commercial scale production of RION’s Purified Exosome Product™ (PEP) drug substance for late phase clinical supply and beyond.

RION LAUNCHES RION VET TO TRANSFORM ANIMAL HEALTH WITH FIRST-IN-CLASS BIOLOGIC THERAPEUTIC; APPOINTS INDUSTRY LEADER MARK HERTHEL AS CEO; ANNOUNCES SERIES A FULFILLMENT RION, a clinical-stage ...